Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Advisory Services Network LLC

Advisory Services Network LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,087 shares of the biopharmaceutical company's stock after buying an additional 8,970 shares during the period. Advisory Services Network LLC's holdings in Gilead Sciences were worth $6,566,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of GILD. XTX Topco Ltd acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $581,000. MML Investors Services LLC boosted its position in shares of Gilead Sciences by 13.2% during the 3rd quarter. MML Investors Services LLC now owns 190,689 shares of the biopharmaceutical company's stock worth $15,987,000 after purchasing an additional 22,191 shares in the last quarter. Groupama Asset Managment grew its stake in shares of Gilead Sciences by 71.1% during the 3rd quarter. Groupama Asset Managment now owns 60,043 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 24,956 shares during the period. Geller Advisors LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at about $216,000. Finally, LRI Investments LLC boosted its holdings in Gilead Sciences by 289.9% during the third quarter. LRI Investments LLC now owns 811 shares of the biopharmaceutical company's stock worth $75,000 after buying an additional 603 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

GILD has been the subject of a number of research analyst reports. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. Morgan Stanley boosted their target price on Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 11th. Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Trading Up 2.2 %

GILD traded up $2.23 on Friday, reaching $103.63. 8,683,683 shares of the company's stock were exchanged, compared to its average volume of 7,501,106. The company has a market cap of $129.04 billion, a price-to-earnings ratio of 280.08, a PEG ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company's 50 day moving average is $108.34 and its 200-day moving average is $96.89.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a $0.79 dividend. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 3.05%. Gilead Sciences's dividend payout ratio is presently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.